医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Mevion Signs Agreement to Bring Proton Therapy to Central Taiwan

2019年11月19日 PM11:00
このエントリーをはてなブックマークに追加


 

LITTLETON, Mass.

Mevion Medical Systems today announced it had signed a collaborative framework agreement with Chung Shan Medical University Hospital and ASYS Corp to provide advanced proton therapy in Central Taiwan. This agreement followed the formation of a partnership between Mevion and ASYS Corp, a leading provider of system integration engineering, sales, and services for the biomedical healthcare industry since 2003.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005337/en/

During the signing ceremony for the collaborative framework agreement, Chien-Ning Huang, M.D., Ph.D., President of Chung Shan Medical University Hospital, James Meng, Ph.D., President of Mevion Medical Systems, and Edward Lee, President of ASYS Corp. signed the agreement on behalf of the three parties. (Photo: Business Wire)

During the signing ceremony for the collaborative framework agreement, Chien-Ning Huang, M.D., Ph.D., President of Chung Shan Medical University Hospital, James Meng, Ph.D., President of Mevion Medical Systems, and Edward Lee, President of ASYS Corp. signed the agreement on behalf of the three parties. (Photo: Business Wire)

Founded in 1966, Chung Shan Medical University Hospital is well established as the leading healthcare provider in the central region of Taiwan. It has been proactively exploring advanced therapies, such as proton therapy, for better patient outcomes.

“We believe incorporating proton therapy to our hospital is a critical, strategic decision to advance our role as a world-class teaching, research, and clinical institution,” said Dr. Chien-Ning Huang, President of Chung Shan Medical University Hospital. “We are excited to be partnering with Mevion to provide industry-leading proton therapy to our patients as well as an excellent platform for research and teaching programs.”

This October, Dr. Huang presented at the Mevion Proton Symposium during the China Society for Radiation Oncology Meeting (CSTRO). As he introduced, there are two operating proton centers in Taiwan and six more in planning or construction phases. Fully taking advantage of its high quality of healthcare and competitive cost of treatment, Taiwan has the potential to become a proton therapy hub for local and international cancer patients.

“Proton therapy and clinical sciences are rapidly advancing in Taiwan. Next year, the 59th Annual Conference of the Particle Therapy Co-Operative Group will be held here, highlighting the scientific advances being made in Taiwan,” said Dr. James Meng, President of Mevion Medical Systems. “We are honored to be selected by Chung Shan Medical University Hospital in their mission to better serve their patients, which so closely aligns with our own. We are also fortunate to have such a respected and experienced local partner, ASYS, to make this project possible.”

“As a trusted advanced system integrator for the past two decades, we are proud to be bringing this life-saving technology to our market through this partnership with Mevion and Chung Shan Medical University Hospital,” said Edward Lee, President of ASYS Corp.

Proton therapy is a more precise therapeutic radiation to the tumor and less damaging to nearby organs. It is becoming a favored tool among top centers around the world. Mevion provides the most compact and precise proton systems available today and has been selected by leading clinical centers in the U.S., Europe, and China.

About Mevion Medical Systems

Mevion Medical Systems, Inc. is the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients. Mevion is based in Littleton, Massachusetts, with a presence in Europe, and Asia. For more information, please visit www.mevion.com

Follow us on Twitter: @MevionMedical
Connect with us on LinkedIn: Mevion Medical Systems
Like Us on Facebook: MevionMedical

View source version on businesswire.com: https://www.businesswire.com/news/home/20191119005337/en/

CONTACT

Melanie Benton

Mevion Medical Systems

Mbenton@mevion.com 1-978-540-1551

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study
  • Personalis, Inc.新发表的数据显示,新型复合生物标志物NEOPS™可用于预测晚期黑色素瘤患者对癌症免疫治疗药物的应答
  • Society5.0 Acquires a Business Model Patent to Build an AR System That Uses Voice Recognition Technology to Provide Medical Safety, Contributing to the Realization of DX
  • 武田交出稳健的2021财年第一季度业绩,促使公司加速营收增长并延续其在研产品线发展态势
  • Oscar Wylee Announces 100th Store; Further Expansion Planned